STOCK TITAN
  1. Home
  2. Sec-filings
  3. BEIGF
  4. [Form 4] BeOne Medicines Ltd. Insider Trading Activity

BeOne Medicines (ONC) SVP granted performance share units vesting 2027–2028

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.

BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.

Positive

  • None.

Negative

  • None.
Insider Lee Chan Henry
Role SVP, General Counsel
Type Security Shares Price Value
Grant/Award Ordinary Shares 65,390 $0.00 --
Grant/Award Ordinary Shares 29,874 $0.00 --
Holdings After Transaction: Ordinary Shares — 288,496 shares (Direct)
Footnotes (1)
  1. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lee Chan Henry
(Last) (First) (Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR
(Street)
BASEL V8 4051
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 03/06/2026 A 65,390(1) A $0 288,496 D
Ordinary Shares 03/06/2026 A 29,874(2) A $0 318,370 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.
2. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.
Remarks:
/s/ Qing Nian, as Attorney-in-Fact 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BeOne Medicines (ONC) report for Lee Chan Henry?

BeOne Medicines reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards in the form of earned performance share units on ordinary shares, rather than buying or selling stock in the open market.

How many BeOne Medicines (ONC) shares are covered by the new awards?

The awards cover 65,390 and 29,874 ordinary shares underlying earned performance share units. Each figure represents separate grants tied to performance, with vesting scheduled in future years if service conditions are met.

When do Lee Chan Henry’s BeOne Medicines (ONC) performance share units vest?

The earned performance share units are scheduled to vest in 2027 and 2028. Vesting requires that Lee Chan Henry continue providing service to BeOne Medicines through each applicable vesting date, according to the disclosure footnotes.

Did BeOne Medicines (ONC) SVP buy shares on the open market?

No. The Form 4 shows grant or award acquisitions at a price of $0.00 per share. These are compensation-related performance share units, not open-market purchases or sales, and therefore do not represent discretionary trading activity.

How many BeOne Medicines (ONC) shares does Lee Chan Henry hold after these awards?

After the reported awards, Lee Chan Henry directly holds 318,370 ordinary shares. This figure reflects his position following the latest grant transactions disclosed in the Form 4 filing for BeOne Medicines.

Are the BeOne Medicines (ONC) performance share units subject to accelerated vesting?

Yes. The footnotes state that unvested securities are subject to accelerated vesting upon certain termination events, providing potential early vesting under specified conditions, in addition to the scheduled vesting in 2027 and 2028.